Johnson & Johnson Q2 FY26 EPS slips 0.9% to $2.27; net sales rise 6.6% to $25.31 billion

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Johnson & Johnson posted Q2 2026 net sales of $25.31 billion, up 6.6% year over year.
  • Net earnings edged down 0.1% to $5.53 billion, while diluted EPS slipped 0.9% to $2.27.
  • Innovative Medicine net sales climbed 7.8% to $16.38 billion, while MedTech rose 4.5% to $8.93 billion.
  • Free cash flow was about $8.7 billion, up from $6.21 billion a year earlier.
  • Raised 2026 outlook, projecting reported sales of $100.8 billion to $101.4 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715519699) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.